Subscribe to RSS
DOI: 10.1055/s-0042-100099
Polymyalgia rheumatica
Polymyalgia rheumatica – what’s new?Publication History
Publication Date:
31 March 2016 (online)
Zusammenfassung
Mittels Ultraschall, MRT oder PET-CT lassen sich zusätzlich typische entzündliche Veränderungen im Schulter- und Beckengürtelbereich nachweisen, mittels MRT und PET-CT sogar paravertebral. Neue Klassifikationskriterien beinhalten Alter ≥ 50 Jahre, CRP- und / oder BSG-Erhöhung, Schultergürtelschmerz sowie zwei Algorithmen mit oder ohne Ultraschall. Letzter Algorithmus hat eine höhere Spezifität bei gleicher Sensitivität. Entsprechend neuen Therapieempfehlungen soll die Diagnose möglichst definitiv gestellt werden. Basis -Laboruntersuchungen und Komorbiditäten müssen berücksichtigt werden. Zunächst wird 12,5–25 mg / d Prednisonäquivalent verordnet und dann die Dosis auf 10 mg / d innerhalb von 4–8 Wochen reduziert, gefolgt von einer 4-wöchentlichen Reduktion um je 1 mg. Bei Risiken und Begleiterkrankungen kann zusätzlich Methotrexat verordnet werden. Verlaufskontrollen sollen innerhalb des 1. Jahres alle 4–8 Wochen erfolgen.
Abstract
Ultrasound, MRI and PET-CT reveal a typical anatomical distribution of inflammation in the shoulder and pelvic girdle. MRI and PET-CT may additionally show inflammation along the spine. New classification criteria include age ≥ 50 years, elevated CRP and / or ESR, and shoulder girdle pain as well as two alternative algorithms with or without ultrasound. The algorithm with ultrasound is more specific but equally sensitive than the other algorithm. According to new recommendations on management diagnosis should be definitely established. Lab tests need to be considered as well as comorbidities. A starting dose of 12.5–25 mg / d prednisone – equivalent is recommended, followed by a dose reduction to 10 mg / d within 4–8 weeks. Afterwards the dose should be reduced by 1 mg every 4 weeks. Methotrexate might be added in patients with significant risks and comorbidities. Follow-up visits should occur every 4–8 weeks during the first year.
-
Literatur
- 1 Schmidt WA. Polymyalgia rheumatica. Z Rheumatol 2013; 72: 59-65
- 2 Mackie SL, Koduri G, Hill CL et al. Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. RMD Open 2015; 1: e000100
- 3 Camellino D, Paparo F, Morbelli S et al. Interspinous bursitis is common in polymyalgia rheumatica, but is not associated with spinal pain. Arthritis Res Ther 2014; 16: 492
- 4 Schmidt WA. Imaging in vasculitis. Best Pract Res Clin Rheumatol 2013; 27: 107-118
- 5 Dasgupta B, Cimmino MA, Maradit-Kremers H et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism / American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012; 71: 484-492
- 6 Macchioni P, Boiardi L, Catanoso M et al. Performance of the new 2012 EULAR / ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis 2014; 73: 1190-1193
- 7 Dejaco C, Singh Y, Perel P et al. Current evidence for therapeutic interventions and prognostic factors in Polymyalgia Rheumatica. Ann Rheum Dis 2015; 74: 1808-1817
- 8 Dejaco C, Singh YP, Perel P et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism / American College of Rheumatology collaborative initiative. Ann Rheum Dis 2015; 74: 1799-1807
- 9 Schmidt WA. Polymyalgia rheumatica (PMR) und Riesenzellarteriitis (Arteriitis temporalis). In: Jung N, Mayet WJ, Mertens PR et al., Hrsg. Rationelle Diagnostik und Therapie in der Inneren Medizin. 42. Lieferung, München: Elsevier; 2015
- 10 Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int 2013; 2013: 120 638
- 11 Izumi K, Kuda H, Ushikubo M et al. Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. RMD Open 2015; 1: e000162